Fibroblast growth factor 21 was reported to have anti-hyperglycemic and anti-hyperlipidemic properties in diabetic rodent 13 and monkey 14 models, and hyperglycaemia and hyperlipidaemia were thought to be the major contributors to DCM 2. Here, FGF21 is linked to Hyperglycemia.